Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated Plasmodium falciparum malaria in children on the rainy south-east coast of Madagascar
Authors:
- Judickaëlle IrinantenainaJIJudickaëlle Irinantenaina
- Gwénaëlle CarnGCGwénaëlle Carn
- Dina Ny Aina Liantsoa RandriamiarinjatovoDRDina Ny Aina Liantsoa Randriamiarinjatovo
- Aina Nirina HarimananaAHAina Nirina Harimanana
- Seheno RazanatsiorimalalaSRSeheno Razanatsiorimalala
- Raphael HotahieneRHRaphael Hotahiene
- Milijaona RandrianarivelojosiaMRMilijaona Randrianarivelojosia
Open Access
- 30 August 2023
- journal article
- research article
- Published by EDP Sciences in Parasite
- Vol. 30, 32
Abstract
Malaria is a major public health problem in Madagascar, particularly in coastal areas. We conducted a randomized, controlled, parallel-group study of artemisinin-based combination therapy (ACT) in Mananjary and Farafangana, two localities on the rainy south-east coast of Madagascar, from March to September 2018. The efficacy and safety of artesunate + amodiaquine (ASAQ) and artemether + lumefantrine (AL) were assessed according to the WHO protocol with a 28-day follow-up. Children aged 6 months to 14 years with uncomplicated Plasmodium falciparum malaria were randomized to receive ASAQ or AL for three days (1:1). 347/352 (98.5%) randomized patients reached the study endpoint on day 28. Crude adequate clinical and parasitological response (ACPR) rates were 100% (95% CI: 98.8–100%) in the ASAQ group and 96% (95% CI: 93.1–98.9%) in the AL group (per protocol population). However, the PCR-corrected ACPR rate was 97.7% (95% CI: 95.4–100%) in the AL group. Two cases of recrudescence and three of re-infection were observed. Mild and moderate adverse events, including gastrointestinal and/or nervous disorders, were reported in 11.9% (42/352) of patients. We found that ASAQ and AL were safe and efficacious for treating uncomplicated P. falciparum malaria. They may be used for treatment at health facilities and at the community level, and for mass drug administration campaigns.Keywords
Funding Information
- US Agency for International Development (Grant No. AID-687-G-13-00003)
This publication has 33 references indexed in Scilit:
- Is the A578S Single-Nucleotide Polymorphism inK13-propellera Marker of Emerging Resistance to Artemisinin AmongPlasmodium falciparumin Africa?: Table 1.The Journal of Infectious Diseases, 2015
- Severe MalariaTropical Medicine & International Health, 2014
- In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in MozambiqueMalaria Journal, 2014
- Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysisMalaria Journal, 2009
- Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malariaMalaria Journal, 2009
- Identification and bioinformatic characterization of a multidrug resistance associated protein (ABCC) gene in Plasmodium bergheiMalaria Journal, 2009
- The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidenceMalaria Journal, 2008
- Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New GuineaMalaria Journal, 2008
- How much fat is necessary to optimize lumefantrine oral bioavailability?Tropical Medicine & International Health, 2007
- WHO — Toxicity Criteria1998